Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis

Assiut University50 enrolled

Overview

Patients diagnosed with Behcet's disease will be randomized to administeration of hydroxychloroquine. Assessment will be done for the patients at baseline and every one month in the first three months and then quarterly for one year.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Behcet's Syndrome, Vascular Type

Interventions

HydroxychloroquineDRUG

the drug will be taken by one group of the patients daily at a dose of 400mg

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients diagnosed with Behcet's disease on any DMARDs Exclusion Criteria: * Patients with critical conditions * Patients with hypersensitivity or adverse drug reactions to hydroxychloroquine.

Locations (1)

Assiut University Hospital

Asyut, Egypt

RECRUITING

Outcomes

Primary Outcomes

Prevention of the recurrence of thrombotic events

number of relapses is expected to fall with the longterm use of the drug

Time frame: 6 months- one year

Central Contacts

Alaa Mohamed, Post-doctor

CONTACT

+20882413177 a.a.a.mohamed@aun.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.